Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

Bayer

Status: Completed

Conditions: Hypertension

Treatments: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291); Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide

Study type: Observational

Funder types: Industry

Identifiers

NCT00927537

13599

KL0810CH (Other Identifier)

Details and patient eligibility

About

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Enrollment: 2,052 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertensive patients seen by the physician requiring antihypertensive treatment

Exclusion criteria

• According to the local drug information

Trial design

2,052 participants in 2 patient groups

Group 1

Treatment:

Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

Group 2

Treatment:

Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide